Avanir completes $10.6 million financing
This article was originally published in Scrip
Executive Summary
Avanir Pharmaceuticals has raised $10.6 million to fund the development and commercialisation of its pseudobulbar affect (PBA) treatment Zenvia (dextromethorphan plus quinidine sulphate).